Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Target Capture Sequencing Service

July 21, 2011 12:35 pm | News | Comments

Beckman Coulter Genomics offers an automated, target capture sequencing service for targeted next generation sequencing.


Scripps Research Scientists Create Heroin Vaccine

July 21, 2011 12:32 pm | News | Comments

Researchers at The Scripps Research Institute have developed a vaccine against a heroin high and have proven its therapeutic potential in animal models.


Imaging Data Supports Davunetide Effects

July 21, 2011 12:28 pm | News | Comments

Allon Therapeutics Inc. announced findings that 12 weeks of treatment with davunetide, the company’s lead product, appears to prevent cortical thinning of important parts of the brains of schizophrenia patients.


Cellectis Bioresearch and Lonza Achieve Milestone on Cell Line

July 21, 2011 12:26 pm | News | Comments

Cellectis bioresearch and Lonza announce that they have reached a milestone in the development of a newly bioengineered cell line.


GNS and NCI To Study Lung Cancer Data

July 21, 2011 12:21 pm | News | Comments

GNS Healthcare, Inc. (GNS) and  the National Cancer Institute (NCI) will develop a supercomputing platform that can uncover cause-and-effect mechanisms for lung cancer hidden in data sets assembled from imaging, genetics, pathology, and other areas.


Scil Technology Establishes Independent Service Unit

July 21, 2011 12:15 pm | News | Comments

Scil Technology GmbH has established an independent service unit named formycon, which will provide protein characterization, formulation development, drug product manufacturing,  process development, quality control, and analytics services.


Beaufort Adds Quality Oversight Services

July 21, 2011 12:12 pm | News | Comments

Beaufort LLC, has added quality oversight to its services for clients in the pharmaceutical, diagnostic, and medical device industries.


Almac Wins Quality Award

July 21, 2011 12:06 pm | News | Comments

Almac’s Clinical Services business unit was presented with the ASQ Philadelphia Section Large Company Member of the Year award at the section’s awards dinner.


Kathy Freeman Joins ACR Image Metrix

July 21, 2011 12:02 pm | News | Comments

Kathy Freeman has joined ACR Image Metrix as business development manager for the East Coast.


Digital Slide Scanner

July 21, 2011 9:52 am | Product Releases | Comments

Leica Microsystems has released its SCN400 F combined fluorescent and brightfield digital slide scanner. The SCN400 F brings together Leica’s brightfield slide scanning capabilities and multi-channel fluorescence imaging in a single platform.


Sample Preservative

July 21, 2011 7:41 am | Product Releases | Comments

Thermo Fisher Scientific Inc. released the AssayAssure sample collection, transport, and storage products. AssayAssure is the one of the most flexible, widely applicable, and longest-acting universal preservatives currently available.


Piercing Tips

July 21, 2011 7:29 am | Product Releases | Comments

Hamilton Robotics introduces disposable CO-RE Piercing Tips for its MICROLAB STAR and NIMBUS automated liquid handling platforms. These tips are designed to pierce septa, sealing mats, and foils on tubes and plates.


Evolution Spectrophotometer Wins R & D 100

July 21, 2011 7:09 am | News | Comments

Thermo Fisher Scientific Inc. announced that its Evolution 200 series of next-generation UV-Visible spectrophotometers has been named one of the most technologically significant products of the past 12 months by R&D Magazine.


Dynavax Vaccine Having Consistency Issues

July 21, 2011 7:05 am | News | Comments

Dynavax Technologies Corp. has reported a setback in a late-stage trial of its hepatitis B vaccine. The company said one production lot of Heplisav had a higher concentration of antibodies than the other two lots.


Gilead AIDS Drug on Par with Raltegravir

July 21, 2011 7:00 am | News | Comments

Gilead Sciences, Inc. announced Phase 3 clinical trial results showing that elvitegravir, an antiviral being evaluated for the treatment of HIV-1, was non-inferior to raltegravir after 48 weeks of therapy.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.